Novavax Inc on Monday reported late-stage data from its US-based clinical trial showing its vaccine is more than 90 percent effective against COVID-19 across a variety of variants of the virus.
The company said it intended to apply for regulatory approval of its Covid-19 vaccine by the third quarter of 2021.
"Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines," said Stanley C. Erck, Novavax's president and chief executive. "Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines."
Novavax also announced plans to make 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the year. It is also easily transportable, as it does not have to be stored at ultra-low temperatures.
Novavax's protein-based COVID-19 vaccine (NVX-CoV2373) was more than 93 percent effective against the predominant variants of COVID-19 that have been of concern among scientists and public health officials, Novavax said.
The company said it intended to apply for regulatory approval of its Covid-19 vaccine by the third quarter of 2021.
"Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines," said Stanley C. Erck, Novavax's president and chief executive. "Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines."
Novavax also announced plans to make 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the year. It is also easily transportable, as it does not have to be stored at ultra-low temperatures.
Novavax's protein-based COVID-19 vaccine (NVX-CoV2373) was more than 93 percent effective against the predominant variants of COVID-19 that have been of concern among scientists and public health officials, Novavax said.
